CRISPR Therapeutics AG (CRSP): Price and Financial Metrics

CRISPR Therapeutics AG (CRSP): $69.55

0.46 (+0.67%)

POWR Rating

Component Grades








Add CRSP to Watchlist
Sign Up

Industry: Biotech




#183 of 342

in industry

CRSP Price/Volume Stats

Current price $69.55 52-week high $76.19
Prev. close $69.09 52-week low $37.55
Day low $69.55 Volume 24,822
Day high $69.55 Avg. volume 1,339,268
50-day MA $50.13 Dividend yield N/A
200-day MA $52.30 Market Cap 5.52B

CRSP Stock Price Chart Interactive Chart >


  • CRSP scores best on the Growth dimension, with a Growth rank ahead of 94.63% of US stocks.
  • The strongest trend for CRSP is in Momentum, which has been heading down over the past 177 days.
  • CRSP ranks lowest in Stability; there it ranks in the 1st percentile.

CRSP Stock Summary

  • Of note is the ratio of CRISPR THERAPEUTICS AG's sales and general administrative expense to its total operating expenses; just 4.57% of US stocks have a lower such ratio.
  • CRSP's price/sales ratio is 24.84; that's higher than the P/S ratio of 95.47% of US stocks.
  • As for revenue growth, note that CRSP's revenue has grown 1,106.49% over the past 12 months; that beats the revenue growth of 99.2% of US companies in our set.
  • Stocks that are quantitatively similar to CRSP, based on their financial statements, market capitalization, and price volatility, are RVMD, XBIT, CKPT, RLAY, and NRIX.
  • CRSP's SEC filings can be seen here. And to visit CRISPR THERAPEUTICS AG's official web site, go to

CRSP Valuation Summary

  • CRSP's price/earnings ratio is -9.7; this is 139.92% lower than that of the median Healthcare stock.
  • CRSP's price/sales ratio has moved down 345.2 over the prior 86 months.

Below are key valuation metrics over time for CRSP.

Stock Date P/S P/B P/E EV/EBIT
CRSP 2023-11-03 23.8 2.2 -9.7 -9.1
CRSP 2023-11-02 21.6 2.0 -8.8 -8.2
CRSP 2023-11-01 20.4 1.9 -8.4 -7.7
CRSP 2023-10-31 18.2 1.7 -7.4 -6.8
CRSP 2023-10-30 18.2 1.7 -7.4 -6.8
CRSP 2023-10-27 18.1 1.7 -7.4 -6.8

CRSP Growth Metrics

    Its year over year net income to common stockholders growth rate is now at 179.43%.
  • Its 5 year net cashflow from operations growth rate is now at 187.22%.
  • Its 5 year cash and equivalents growth rate is now at 180.78%.
Over the past 33 months, CRSP's revenue has gone down $275,499,000.

The table below shows CRSP's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 14.091 -468.451 -680.848
2022-06-30 14.821 -444.562 -633.452
2022-03-31 915.364 504.396 311.607
2021-12-31 914.963 538.972 377.661
2021-09-30 902.434 543.798 411.87
2021-06-30 901.758 549.427 446.584

CRSP's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CRSP has a Quality Grade of C, ranking ahead of 73.06% of graded US stocks.
  • CRSP's asset turnover comes in at 0.441 -- ranking 101st of 681 Pharmaceutical Products stocks.
  • CDTX, NVS, and SEEL are the stocks whose asset turnover ratios are most correlated with CRSP.

The table below shows CRSP's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.441 1 0.579
2021-03-31 0.001 1 -0.839
2020-12-31 0.001 1 -1.179
2020-09-30 0.067 1 -1.230
2020-06-30 0.301 1 0.242
2020-03-31 0.352 1 0.539

CRSP Price Target

For more insight on analysts targets of CRSP, see our CRSP price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $162.94 Average Broker Recommendation 1.55 (Moderate Buy)

CRISPR Therapeutics AG (CRSP) Company Bio

CRISPR Therapeutics AG focuses on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. The company is based in Basel, Switzerland.

CRSP Latest News Stream

Event/Time News Detail
Loading, please wait...

CRSP Latest Social Stream

Loading social stream, please wait...

View Full CRSP Social Stream

Latest CRSP News From Around the Web

Below are the latest news stories about CRISPR THERAPEUTICS AG that investors may wish to consider to help them evaluate CRSP as an investment opportunity.

5 Biotech Stocks Likely to Thrive as Industry Prospects Look Bright

New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position GILD, CRSP, ACAD, DVAX and LGND well amid volatility.

Yahoo | November 22, 2023

Is CRISPR Therapeutics the Best Gene-Editing Stock?

A striking analogy can be drawn between the development of monoclonal antibodies and the emergence of CRISPR-based gene editing. Since the first Food and Drug Administration (FDA) approval of a monoclonal antibody in 1986, the field has expanded rapidly, and several of the top-selling therapies of all time have originated from this technology. If CRISPR gene editing follows a similar trajectory, early shareholders in companies that develop the groundbreaking tech ought to reap huge rewards in the coming decades.

Yahoo | November 22, 2023

3 Biotech Stocks That Could Be Millionaire Makers

In my view, these three players, held as part of a diversified portfolio, could be millionaire makers. CRISPR Therapeutics (NASDAQ: CRSP) just reached a huge moment in its story as a company. Along with partner Vertex Pharmaceuticals, it earned the world's first authorization for a gene-editing treatment that uses the "CRISPR technique."

Yahoo | November 22, 2023

These Stocks Are Exploding In The November Stock Market Rally

The November rally continues with more names joining in. These five stock have outperformed with gains as high as 85% in November.

Yahoo | November 21, 2023

Google’s Bard AI Says These 3 Stocks Will Rise 1,000%

Google's Bard has been among the best stock pickers, and thinks these three stocks have quadruple-digit upside potential.

Omor Ibne Ehsan on InvestorPlace | November 20, 2023

Read More 'CRSP' Stories Here

CRSP Price Returns

1-mo N/A
3-mo 37.64%
6-mo 7.00%
1-year 26.94%
3-year -45.20%
5-year 81.45%
YTD 71.09%
2022 -46.36%
2021 -50.51%
2020 151.39%
2019 113.18%
2018 21.68%

Continue Researching CRSP

Here are a few links from around the web to help you further your research on CRISPR Therapeutics AG's stock as an investment opportunity:

CRISPR Therapeutics AG (CRSP) Stock Price | Nasdaq
CRISPR Therapeutics AG (CRSP) Stock Quote, History and News - Yahoo Finance
CRISPR Therapeutics AG (CRSP) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!